Three telehealth providers offer FDA-approved Wegovy oral semaglutide in 2026, each with separate medication and membership charges that stack into different total costs. We normalize the billing structures and show the 12-month cost for each.

MEDVi sells two different oral routes under one banner: a compounded semaglutide dissolvable tablet priced about $70 a month over MEDVi's injection rate (no tablet total published), and a branded Wegovy pill pathway billed as membership plus medication. This review separates the two, explains what FDA approval does and does not cover, and compares them with PlexusDx oral options.